Patent Issued for Engineered lipase variants (USPTO 11987823).
In: Pharma Business Week, 2024-06-13, S. 4435-4435
serialPeriodical
Zugriff:
The given text is a patent issued to Societe des Produits Nestle S.A. for engineered lipase variants. These variants have been optimized to improve stability and function under different conditions, including acidic pH levels. The patent includes information about the specific amino acid sequence and substitutions of the recombinant lipase, as well as methods for producing and purifying it. The technology has potential applications in therapeutic and nutritional purposes, particularly in the treatment of pancreatic enzyme insufficiency. For more detailed information, please refer to the full patent. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Engineered lipase variants (USPTO 11987823).
|
---|---|
Zeitschrift: | Pharma Business Week, 2024-06-13, S. 4435-4435 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|